Study 1 of 1 for search of: sammpris
Previous Study Return to Search Results Next Study

Full Text View
Tabular View
No Study Results Posted
Related Studies
Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS)
This study is currently recruiting participants.
Verified by Medical University of South Carolina, February 2009
First Received: December 7, 2007   Last Updated: February 12, 2009   History of Changes
Sponsor: Medical University of South Carolina
Collaborator: National Institutes of Health (NIH)
Information provided by: Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT00576693
  Purpose

PRIMARY HYPOTHESIS:

Compared with intensive medical therapy alone, intracranial angioplasty and stenting combined with intensive medical therapy will decrease the risk of the primary endpoint by 35% over a mean follow-up of two years in high-risk patients (patients with 70% - 99% intracranial stenosis who had a TIA or stroke within 30 days prior to enrollment) with symptomatic stenosis of a major intracranial artery.

SUMMARY:

The best treatment for prevention of another stroke or TIA in patients with narrowing of one of the arteries in the brain is uncertain. A common treatment is the use of anti-clotting medications to prevent blood clots from forming in the narrowed vessel. There are a variety of medicines used for this purpose. These medications are usually taken for the rest of a patient's life.

However, a treatment that has been used successfully together with anti-clotting medications in patients with narrowing of the blood vessels of the heart is now being studied in the blood vessels of the brain. This treatment is called stenting.

Recent research has also indicated a benefit in prevention of recurring stroke by Intensive Medical Therapy, which is defined as treating risk factors for stroke like high blood pressure, elevated LDL (low density lipids - the "bad" form of cholesterol) and diabetes. The purpose of this study is to compare the safety and effectiveness of either Intensive Medical Therapy PLUS Stenting or Intensive Medical Therapy ONLY in preventing stroke, heart attacks or death.

The study will enroll patients over a 5 year period. Each participant will be involved in the study for a minimum of 1 year and a maximum of 3 years.

Fifty different medical centers in the United States are part of this study. Both the Clinical Coordinating Center and the Statistical Coordinating Center for the entire study will be located at Emory University.


Condition Intervention Phase
Ischemic Stroke
Device: Wingspan intracranial stent with Gateway balloon
Other: Intensive Medical Therapy
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Parallel Assignment
Official Title: Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis

Resource links provided by NLM:


Further study details as provided by Medical University of South Carolina:

Primary Outcome Measures:
  • To determine whether intracranial stenting (Wingspan stent) with intensive medical therapy is superior to the medical therapy alone for preventing second stroke in high-risk patients with symptomatic stenosis of a major intracranial artery. [ Time Frame: mean of 2 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 764
Study Start Date: October 2008
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Stenting arm
Device: Wingspan intracranial stent with Gateway balloon
Wingspan intracranial stent with Gateway balloon
Other: Intensive Medical Therapy
Management of blood pressure, lipids, and other risk factors for vascular events.Patients treated with lipid-lowering agents, antihypertensives, aspirin, glucose-lowering agents as indicated by their individual medical condition.
2: Experimental
Medical arm
Other: Intensive Medical Therapy
Management of blood pressure, lipids, and other risk factors for vascular events.Patients treated with lipid-lowering agents, antihypertensives, aspirin, glucose-lowering agents as indicated by their individual medical condition.

  Eligibility

Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA

  1. TIA or non-severe stroke within 30 days of enrollment attributed to 70-99% stenosis of a major intracranial artery (carotid artery, MCA stem (M1), vertebral artery, or basilar artery)

    • may be diagnosed by TCD, MRA, or CTA to qualify for angiogram performed as part of the study protocol but must be confirmed by catheter angiography for enrollment in the trial

  2. Modified Rankin score of ≤ 3
  3. Target area of stenosis in an intracranial artery that has a normal diameter of 2.00 mm to 4.50 mm
  4. Target area of stenosis is less than or equal to 14 mm in length
  5. Age ≥ 30 years and ≤ 80 years.

    • Patients 30-49 years are required to meet at least one additional criteria (i-vi) provided in the table below to qualify for the study. This additional requirement is to increase the likelihood that the symptomatic intracranial stenosis in patients 30-49 years is atherosclerotic.

    i. insulin dependent diabetes for at least 15 years ii. at least 2 of the following atherosclerotic risk factors: hypertension (BP > 140/90 or on antihypertensive therapy); dyslipidemia (LDL > 130 mg /dl or HDL < 40 mg/dl or fasting triglycerides > 150 mg/dl or on lipid lowering therapy); smoking; non-insulin dependent diabetes or insulin dependent diabetes of less than 15 years duration; family history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery in parent or sibling who was < 55 years of age for men or < 65 for women at the time of the event ii. history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease iv. any stenosis of an extracranial carotid or vertebral artery, another intracranial artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery that was documented by non-invasive vascular imaging or catheter angiography and is considered atherosclerotic v. aortic arch atheroma documented by non-invasive vascular imaging or catheter angiography vi. any aortic aneurysm documented by non-invasive vascular imaging or catheter angiography that is considered atherosclerotic

  6. Negative pregnancy test in a female who has had any menses in the last 18 months
  7. Patient is willing and able to return for all follow-up visits required by the protocol
  8. Patient is available by phone
  9. Patient understands the purpose and requirements of the study, can make him/herself understood, and has provided informed consent

EXCLUSION CRITERIA

  1. Tandem extracranial or intracranial stenosis (70%-99%) or occlusion that is proximal or distal to the target intracranial lesion (NOTE: an exception is allowed if the occlusion involves a single vertebral artery proximal to a symptomatic basilar artery stenosis and the contralateral vertebral artery is supplying the basilar artery)
  2. Bilateral intracranial vertebral artery stenosis of 70%-99% and uncertainty about which artery is symptomatic (e.g. if patient has pontine, midbrain, or temporal - occipital symptoms)
  3. Stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebral artery) or intracranial artery within 30 days prior to expected enrollment date
  4. Previous treatment of target lesion with a stent, angioplasty, or other mechanical device, or plan to perform staged angioplasty followed by stenting of target lesion
  5. Plan to perform concomitant angioplasty or stenting of an extracranial vessel tandem to an intracranial stenosis
  6. Presence of intraluminal thrombus proximal to or at the target lesion
  7. Any aneurysm proximal to or distal to stenotic intracranial artery
  8. Intracranial tumor (except meningioma) or any intracranial vascular malformation
  9. CT or angiographic evidence of severe calcification at target lesion
  10. Thrombolytic therapy within 24 hours prior to enrollment
  11. Progressive neurological signs within 24 hours prior to enrollment
  12. Brain infarct within previous 30 days of enrollment that is of sufficient size (> 5 cms) to be at risk of hemorrhagic conversion during or after stenting
  13. Any hemorrhagic infarct within 14 days prior to enrollment
  14. Any hemorrhagic infarct within 15 - 30 days that is associated with mass effect
  15. Any history of a primary intracerebral (parenchymal) hemorrhage (ICH)
  16. Any other intracranial hemorrhage (subarachnoid, subdural, epidural) within 30 days
  17. Any untreated chronic subdural hematoma of greater than 5 mm in thickness
  18. Intracranial arterial stenosis due to arterial dissection, Moya Moya disease; any known vasculitic disease; herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; any other intracranial infection; any intracranial stenosis associated with CSF pleocytosis; radiation induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; benign angiopathy of central nervous system; post-partum angiopathy; suspected vasospastic process, suspected recanalized embolus
  19. Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within three months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction less than 30%
  20. Known allergy or contraindication to aspirin, clopidogrel, heparin, nitinol, local or general anesthesia
  21. History of life-threatening allergy to contrast dye. If not life threatening and can be effectively pretreated, patient can be enrolled at physician's discretion
  22. Active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets < 100,000, hematocrit < 30, INR > 1.5, clotting factor abnormality that increases the risk of bleeding, current alcohol or substance abuse, uncontrolled severe hypertension (systolic pressure > 180 mm Hg or diastolic pressure > 115 mm Hg), severe liver impairment (AST or ALT > 3 x normal, cirrhosis), creatinine > 3.0 (unless on dialysis)
  23. Major surgery (including open femoral, aortic, or carotid surgery) within previous 30 days or planned in the next 90 days after enrollment
  24. Indication for heparin beyond enrollment (medical arm) or stenting procedure (stenting arm) or indication for warfarin beyond enrollment
  25. Severe neurological deficit that renders the patient incapable of living independently
  26. Dementia or psychiatric problem that prevents the patient from following an outpatient program reliably
  27. Co-morbid conditions that may limit survival to less than 3 years
  28. Pregnancy or of childbearing potential and unwilling to use contraception for the duration of this study
  29. Enrollment in another study that would conflict with the current study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00576693

Contacts
Contact: Bethany F Lane, RN,BSN,CCRC 678-429-1012 bethany.lane@emory.edu
Contact: Rie Calcaterra 678-557-6466 calcater@musc.edu

  Show 57 Study Locations
Sponsors and Collaborators
Medical University of South Carolina
Investigators
Principal Investigator: Marc I Chimowitz, MBChB Medical University of South Carolina
  More Information

No publications provided

Responsible Party: Medical University of South Carolina ( Marc Chimowitz, MBChB )
Study ID Numbers: R01NS058728-01A1, R01NS058728-01A1
Study First Received: December 7, 2007
Last Updated: February 12, 2009
ClinicalTrials.gov Identifier: NCT00576693     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Medical University of South Carolina:
ischemic stroke
intracranial stenting
vascular risk factor management

Additional relevant MeSH terms:
Cerebral Infarction
Stroke
Nervous System Diseases
Vascular Diseases
Central Nervous System Diseases
Cardiovascular Agents
Brain Diseases
Antihypertensive Agents
Cerebrovascular Disorders
Pharmacologic Actions
Therapeutic Uses
Brain Ischemia
Cardiovascular Diseases
Brain Infarction

ClinicalTrials.gov processed this record on February 08, 2010